This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.

Ono has an exclusive option to discover, develop, and commercialize drug candidates based on RNA-editing drug sequences designed by Jorna.